WATCHMAN FLX™ IS A PROVEN AND SAFE THERAPY FOR YOUR NVAF PATIENTS:

1. It reduces the risk of stroke in NVAF patients as effectively as OAC
2. It reduces the long-term risk of bleeding associated with OAC
3. Implanted in 150,000+ patients worldwide.

PROTECT YOUR PATIENTS FOR LIFE WITH WATCHMAN FLX™

FIND AN IMPLANTING CENTRE NEAR YOU AT:

www.watchman.com/uk

Refer your patient to one of the medical centres across EU that is certified to implant WATCHMAN FLX™.

Asses the risks of stroke and bleeding in your NVAF patients with the **Stroke-Bleed Risks Calculator app** available on the Apple App-Store or Android Google Play.

SH-1035103-AA Printed in Germany by medicalvision.

Boston Scientific
Advancing science for life™

www.bostonscientific.eu

DINSH0294EA

PROTECT YOUR PATIENTS FOR LIFE WITH WATCHMAN FLX™

Boston Scientific
Advancing science for life™

WATCHMAN™
INTEGRATED LAAC SOLUTIONS

ONE TIME.
FOR A LIFETIME.

PATIENTS WITH ATRIAL FIBRILLATION ARE AT AN INCREASED RISK OF STROKE

Atrial Fibrillation (AF) increases the risk of stroke by 5 times.[1] **Strokes in patients with AF are:**

#1 Cause of long-term disability

#3 Leading cause of death

In non-valvular atrial fibrillation patients (NVAF), 90 % of left atrium blood clots originate in the left atrial appendage (LAA).[2]



1. AF causes blood to stagnate in the LAA
2. The stagnant blood becomes an ideal environment for a thrombus or blood clot to form
3. The blood clot dislodges from the LAA and travels through the arterial system
4. The embolism lodges itself in the blood vessels of the brain, restricting blood flow and causing a stroke

TREATMENT OPTIONS

Oral anticoagulation (OAC) with vitamin K antagonists (VKA) or non-VKA oral anticoagulants (NOAC) are good treatment options for some patients.

HOWEVER

- Discontinuation of the OAC therapy rates remain high (at 2 years, 50% of patients on VKA and 30% on NOAC treatment)[3]
- Bleeding risks are not eliminated
- Other AF patients have contraindications to OAC, or a history of bleeding on OAC, or may suffer a systemic thromboembolisation event despite adequate OAC

PROTECT YOUR PATIENTS FOR LIFE WITH WATCHMAN FLX™ LEFT ATRIAL APPENDAGE CLOSURE DEVICE

WATCHMAN FLX™ is a one-time, minimally invasive procedure that reduces the risk of stroke and the risk of bleeding that comes with the use of OACs in non-valvular atrial fibrillation patients (NVAF).



The WATCHMAN FLX™ device is designed to close off the LAA, preventing the migration of blood clots.

Designed to treat the widest range of patient anatomies

It is available in 5 different sizes to adapt to individual LAA anatomy (from 20 to 35 mm diameter).

20 mm | 24 mm | 27 mm | 31 mm | 35 MM



WHICH OF YOUR NVAF PATIENTS ARE RIGHT FOR WATCHMAN FLX™?

The WATCHMAN FLX™ device may be an appropriate option for your NVAF patients who:

1. Are at an increased risk of stroke (CHA_2DS_2-VASc≥2)*
2. Are contraindicated or intolerant to oral anticoagulants.
3. Have a history of bleeding while taking oral anticoagulants
4. Have suffered a prior stroke or transient ischemic attack (TIA)

- Patients who are **not eligible** for OAC therapy can now **benefit** from a therapy to protect them from stroke
- Patients who are **eligible** for OAC therapy can **reduce** the risk of bleeding that comes with life-long usage of OAC

*C=congestive heart failure; H=hypertension; A2=age≥75 years; D=diabetes mellitus; S2=prior stroke or transient ischemic attack or thromboembolism; V=vascular disease; A=age 65–74 years; Sc=sex category

PATIENT PROFILES*

NIKOLAS, 77 Years contraindicated to OAC

Occupation: Retired teacher

Medical conditions: NVAF, Hypertension, Previous stroke
CHA_2DS_2-VASc score: 5 – **HAS-BLED score:** 4

Nikolas has a history of bleeding, especially gastrointestinal, which makes him contraindicated to oral anticoagulants.

What approach do you take with your NVAF patients who cannot take OAC?

GWEN, 65 Years previous bleeding events

Occupation: Home healthcare assistant

Medical conditions: NVAF, Hypertension, Previous TIA
CHA_2DS_2-VASc score: 5 – **HAS-BLED score:** 3

Gwen is currently taking 100 mg of aspirin daily. She experienced gastrointestinal bleeding on warfarin and on apixaban. She has been taking only ASA since her last GI bleed.

What approach do you take with your NVAF patients who experienced bleeding?

ABIGAIL, 72 Years high risk for bleeding

Occupation: Retired flight attendant

Medical conditions: NVAF, Hypertension, Diabetes
CHA_2DS_2-VASc score: 4 – **HAS-BLED score:** 3

Abigail has severe kidney dysfunction, which precludes her from being able to use several kinds of oral anticoagulants. Her physician also believes she is at high risk for bleeding as a result of her kidney failure.

What approach do you take with your NVAF patientswho are at a high risk of bleeding?

Case description for educational purposes; not real patient cases.

HOW WATCHMAN FLX™ WORKS

WATCHMAN FLX™ is designed to permanently close the left atrial appendage (LAA) and reduce the risk of thromboembolism.

Minimally invasive, permanent implant

Procedure time typically 1 hour or less

Patients usually stay in the hospital overnight and return home next day

*In the **EWOLUTION** prospective registry, WATCHMAN™ was successfully implanted in **98.5% of patients.**[*4]*

* The most common reason for the deployment failures was unfavourable anatomy or mismatch between the size of the device and the LAA.

THE WATCHMAN FLX™ PROCEDURE

1



Using a standard percutaneous technique, a guidewire and vessel dilator are inserted into the femoral vein.

2



The implant procedure is performed with fluoroscopy and transesophageal echocardiography (TEE). The interatrial septum is crossed using a standard transseptal access system.

3



The access sheath is advanced over the guidewire into the left atrium and then navigated into the distal portion of the LAA over a pigtail catheter.

4



WATCHMAN FLX™ is deployed and released in the LAA.

5



Heart tissue grows over implant and LAA is permanently sealed; patients remain on OAC for at least 45 days post-procedure.

6



Fully endothelialized device.

> 96%

OF PATIENTS DISCONTINUED OACS AT 45 DAYS[5]

POST PROCEDURE

Following the procedure, physicians may prescribe an individual post-implant medication considering patient preference, stroke and bleeding risk.

Treatment options may include a dual antiplatelet therapy (DAPT) or an oral anticoagulation therapy with warfarin or NOAC (non-Vitamin-K oral anticoagulation)along with aspirin for at least three months.

If the patient receives OAC, switching to DAPT after 45 days could be considered. Aspirin is recommended for at least 12 months post-implant.

WATCHMAN™: A PROVEN THERAPY

The WATCHMAN™ clinical evidence consists of over 5,800 patients studied in 2 randomised trials (with 5 years of follow-up of PROTECT AF and PREVAIL) and multiple prospective registries.

With close to 20 years of experience in clinical trials and real world, WATCHMAN™ is the most studied LAAC device and the only proven with long-term data.



More than

5,800 patients

10,000 patient years of follow-up

Long term data from PROTECT AF and PREVAIL demonstrated that WATCHMAN™ offered comparable stroke risk reduction as well as statistically significant reductions in disabling and fatal stroke* (55%), non-procedure related major bleeding (52%), and mortality (41% CV death) vs. warfarin after 5 years of follow-up.[6]

5-YEAR PATIENT-LEVEL META-ANALYSIS OF PROTECT AF AND PREVAIL

Endpoint	Reduction	Hazard Ratio (95% CI)	P-Value	Statistical Significance
Primary Efficacy	**18%**	0.82 (0.58 – 1.17)	0.27	Non-inferior
All Cause Stroke	**4%**	0.96 (0.60 – 1.54)	0.87	No statistical difference
Disabling / Fatal Stroke*	**55%**	0.45 (0.21 – 0.94)	0.03	Statistically significant
Ischemic Stroke	**N/A**	1.71 (0.94 – 3.11)	0.08	No statistical difference
Hemorrhagic Stroke	**80%**	0.20 (0.07 – 0.56)	0.0022	Statistically significant
Non-procedure related major bleeding	**52%**	0.48 (0.32 – 0.71)	0.0003	Statistically significant
Mortality				
All-Cause	**27%**	0.73 (0.54 – 0.98)	0.04	Statistically significant
CV/Unexplained	**41%**	0.59 (0.37 – 0.94)	0.03	Statistically significant

WATCHMAN FLX™ Group N=732
WARFARIN Group N=382

In a real-world clinical setting, studied in the prospective EWOLUTION registry, WATCHMAN™ at 1 year of follow-up[7] confirmed to be safe and effective in a high risk population showing: 84% reduction in ischemic strokes (annual stroke rate was 1.1%) as compared to no therapy[8] and 48% reduction in major bleeding events (annual major bleeding rate was 2.6%) compared to warfarin.[9]

*Two strokes in PREVAIL are excluded because the baseline MRS score was unavailable.

The patient-level meta-analysis of the PROTECT AF and PREVAIL trials found that the longer a patient has a WATCHMAN™ implant, the greater the reduction in bleeding events.[5]

At 6 months post-procedure, WATCHMAN™ reduced major bleeding events vs warfarin by 72 % (1.0 vs 3.5; P<0.001).[5]

WATCHMAN™ REDUCED BLEEDING EVENTS VS WARFARIN*

The longer a patient has a WATCHMAN™ implant, the greater the reduction in bleeding events.[5]



STUDY DESIGN
The patient-level meta-analysis of the PROTECT AF and PREVAIL trials also compared the relative risk of major bleeding with WATCHMAN and long-term warfarin therapy. In both trials, patients who were randomly assigned to WATCHMAN continued to take warfarin and aspirin 45 days after the procedure. Transesophageal echocardiography was then performed to confirm adequate left atrial appendage (LAA) sealing (peridevice leak <5 mm in diameter). If the LAA was adequately sealed, patients discontinued warfarin and were treated with aspirin and clopidogrel for 6 months after the procedure, followed by ongoing aspirin therapy. If LAA sealing was inadequate, patients remained on warfarin and aspirin and did not receive clopidogrel. Post-hoc analyses were performed at 3 intervals (7 days, 45 days, and 6 months post-procedure) to assess the procedural complications and relative risk to events like major bleeding.[5]

* Major bleeding defined as adverse event that was assigned one of several bleeding codes and was adjudicated by an independent Clinical Events Committee as significant (life-threatening or resulting in hospitalisation , prolongation of hospitalisation, substantial disability, or death).
** PROTECT AF followed patients for five years.

WATCHMAN™ IS SAFE

WATCHMAN™ maintains favorable safety outcomes from clinical studies to real-world experience.

Serious adverse procedure or device related events (SAE)* at 7 days



*EW*OLUTION (Registry on WATCHMAN™ Outcomes in Real-Life Utilisation) is the largest prospective real-life registry with over 1,000 patients studied and more than 70 % of patients contraindicated to OAC.[4]

* SAE: Serious Adverse Event - Composite of vascular complications includes cardiac perforation, pericardial effusion with tamponade, ischemic stroke, device embolisation, and other vascular complications.

REFERENCES

1. Holmes DR, Atrial Fibrillation and Stroke Management: Present and Future. Seminars in Neurology 2010;30:528–536.

2. Blackshear JL and Odell JA, Appendage Obliteration to Reduce Stroke in Cardiac Surgical Patients with Atrial Fibrillation. Annals of Thoracic Surg (1996).

3. Martinez C, et al., Therapy Persistence In Newly Diagnosed Non-Valvular Atrial Fibrillation Treated with Warfarin or Noac, A Cohort Study. Thromb Haemost. 2016; 115:31–39.

4. Boersma LVA et al., Implant Success and Safety of Left Atrial Appendage Closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION Registry. Eur Heart J. 2016;37(31):2465-74.

5. Price MJ, et al., Bleeding outcomes after left atrial appendage closure compared with long-term warfarin. JACC Cardiovasc Interv. 2015;8(15):1925-1932.

6. Holmes DR Jr, et al., Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient level metaanalysis. J Am Coll Cardiol. 2015;65(24):2614-2623.

7. Reddy, V. Y., H. Sievert, et al. (2014). Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: A randomized clinical trial. JAMA 312(19): 1988-1998.

8. Circulatory System Devices Panel: WATCHMAN® Left Atrial Appendage Closure Therapy Sponsor Presentation. 2014 FDA Circulatory System Devices Panel.

9. Reddy VY, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). JACC.2013 Jun 25;61(25):2551-6.

10. Holmes DR et al., Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. JACC 2014; Jul 8;64(1):1-12. **11.** Reddy VY, 5-Year Outcomes After Left Atrial Appendage Closure From the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol. 2017 Dec 19;70(24):2964-2975.

12. Boersma LV et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. Heart Rhythm. 2017 Sep;14(9):1302-1308.

13. Friberg L, et al., Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. European Heart Journal (2012) 33, 1500–1510.

14. Lip GYK, et al., Comparative Validation of a Novel Risk Score forPredicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation. J Am Coll Cardiol. 2011 Jan 11;57(2):173-80.

15. PINNACLE FLX. Doshi, SK. Results Presented at HRS 2020